Pfizer’s $68 billion acquisition of Wyeth last year has turned into a full-employment act for the drugmaker’s outside law firms. Yesterday the company was slapped with a whistleblower lawsuit alleging Wyeth detailers promoted the off-label use of the immunosuppressant drug Rapamune for kidney transplant patients even though the Food and Drug Administration has explicitly warned […]
Last summer, documents uncovered in a lawsuit against Wyeth-Ayerst, the manufacturer of hormone replacement therapy, revealed that 26 journal articles touting HRT for post-menopausal women written after serious risks had become known were ghostwritten by Wyeth consultants. A new study of the five most prolific authors of HRT-related editorials, clinical practice guidelines and reviews over […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
While many big policy changes in America are best-served to happen in the "laboratory" of the state level, allowing for a sort of trial-and-error of democracy, health reform isn't one of them--if you accept the idea that universal (or near-universal) coverage is a goal of reform, that is.
A federal judge in Delaware declared invalid a quartet of Johnson & Johnson's Cordis Corp. subsidiary's patents for drug-eluting stents, canceling a trial set for next month in a patent infringement lawsuit filed by Boston Scientific.
Cordis Corp. will defend the Cypher drug-eluting stent on its home turf in New Jersey in a patent infringement case against Boston Scientific Corp. and Abbott Laboratories.
Kylin's technology is based on what's known as RNA interference, a technique for "gene silencing."
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Pfizer-Wyeth fallout: At a time when many small biotech companies are desperate for cash, neither Pfizer nor Wyeth will be able to enter into new deals anytime soon.